argenex (NASDAQ:ARGX) Posts Earnings Results, Beats Expectations By $0.36 EPS

Key Points

• argenx beat quarterly earnings expectations, reporting $7.80 EPS versus the $7.44 consensus and approximately $1.75 billion in revenue. Product net sales rose 54% year over year to $1.7 billion.
• The stock fell 0.7% to $869.22 despite the strong results, as a testing setback in a VYVGART-related Sjögren’s syndrome study raised concerns about pipeline expansion and overshadowed the earnings beat.
• Analyst sentiment remains generally positive but mixed: the consensus rating is “Moderate Buy” with a $1,148.95 price target, while recent targets ranged from $861 to $1,336.

argenex (NASDAQ:ARGX - Get Free Report) announced its quarterly earnings results on Friday. The company reported $7.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.44 by $0.36, Zacks reports. The firm had revenue of $1.75 billion during the quarter. argenex had a net margin of 32.19% and a return on equity of 43.59%.

argenex Stock Down 0.7%

NASDAQ:ARGX traded down $6.54 during midday trading on Friday, hitting $869.22. The company had a trading volume of 75,220 shares, compared to its average volume of 351,665. The stock's fifty day moving average price is $956.17 and its 200-day moving average price is $885.45. argenex has a 52-week low of $661.85 and a 52-week high of $1,072.75. The company has a market capitalization of $54.67 billion, a PE ratio of 33.44, a P/E/G ratio of 0.82 and a beta of 0.44.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

Analysts Set New Price Targets

Several analysts recently commented on the company. Robert W. Baird upped their target price on argenex from $823.00 to $861.00 and gave the company a "neutral" rating in a report on Friday. Royal Bank Of Canada lowered their target price on argenex from $1,100.00 to $1,025.00 and set an "outperform" rating on the stock in a research report on Tuesday. Jefferies Financial Group reiterated a "buy" rating on shares of argenex in a research note on Monday, September 14th. Wells Fargo & Company lowered their target price on shares of argenex from $1,356.00 to $1,336.00 and set an "overweight" rating for the company in a report on Friday. Finally, Citizens Jmp lifted their target price on argenex from $932.00 to $1,200.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,148.95.

argenex Company Profile

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.